English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/237238
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study

AuthorsSuárez-García, Inés; Moreno, Cristina; Ruiz-Algueró, Marta; Pérez-Elías, María Jesús; Navarro, Marta ; Díez Martínez, Marcos; Viciana, Pompeyo; Pérez-Martínez, Laura; Górgolas-Hernández-Mora, Miguel; Amador, Concha; Zárraga, Miguel Alberto de; Jarrín, Inma
KeywordsHIV infection
Highly active antiretroviral therapy
Cohort studies
Darunavir
Issue Date2020
PublisherBioMed Central
CitationAIDS Research and Therapy 17(45): (2020)
Abstract[Background]: The aim of this study was to investigate the effectiveness and tolerability of the combination elvitegravir/cobicistat/tenofovir/emtricitabine plus darunavir (EVG/COB/TFV/FTC + DRV) in treatment-experienced patients from the cohort of the Spanish HIV/AIDS Research Network (CoRIS).
[Methods]: Treatment-experienced patients starting treatment with EVG/COB/TFV/FTC + DRV during the years 2014–2018 and with more than 24 weeks of follow-up were included. TFV could be administered either as tenofovir disoproxil fumarate or tenofovir alafenamide. We evaluated virological response, defined as viral load (VL) < 50 copies/ml and < 200 copies/ml at 24 and 48 weeks after starting this regimen, stratified by baseline VL (< 50 or ≥ 50 copies/ml at the start of the regimen).
[Results]: We included 39 patients (12.8% women). At baseline, 10 (25.6%) patients had VL < 50 copies/ml and 29 (74.4%) had ≥ 50 copies/ml. Among patients with baseline VL < 50 copies/ml, 85.7% and 80.0% had VL < 50 copies/ml at 24 and 48 weeks, respectively, and 100% had VL < 200 copies/ml at 24 and 48 weeks. Among patients with baseline VL ≥ 50 copies/ml, 42.3% and 40.9% had VL < 50 copies/ml and 69.2% and 68.2% had VL < 200 copies/ml at 24 and 48 weeks. During the first 48 weeks, no patients changed their treatment due to toxicity, and 4 patients (all with baseline VL ≥ 50 copies/ml) changed due to virological failure.
[Conclusions]: EVG/COB/TFV/FTC + DRV was well tolerated and effective in treatment-experienced patients with undetectable viral load as a simplification strategy, allowing once-daily, two-pill regimen with three antiretroviral drug classes. Effectiveness was low in patients with detectable viral loads.
Description© The Author(s) 2020.
Publisher version (URL)http://dx.doi.org/10.1186/s12981-020-00302-2
URIhttp://hdl.handle.net/10261/237238
DOI10.1186/s12981-020-00302-2
E-ISSN1742-6405
Appears in Collections:(IBIS) Artículos
Files in This Item:
File Description SizeFormat 
Efectiveness_Suarez_PV_Art2020.pdf784,13 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.